Adverum Biotechnologies Inc (ADVM)
0.7577
+0.01
(+1.31%)
USD |
NASDAQ |
Mar 24, 16:00
0.76
0.00 (0.00%)
After-Hours: 20:00
Key Stats
Price and Performance | |
---|---|
Market Cap | 74.79M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -44.60% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 0.3590 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 97.89% |
News
Headline
Wire
Time (ET)
MT Newswires
03/07 09:55
Yahoo
03/02 10:23
MT Newswires
11/11 08:06
MT Newswires
11/11 07:00
Globe Newswire
09/30 16:45
Globe Newswire
09/23 16:05
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
03/29/2023* | -- | Results | Q4 2022 | -- | -0.39 | -- | |
11/10/2022 | -- | Results | Q3 2022 | -0.40 | -0.37 | -7.14% | |
08/11/2022 | -- | Results | Q2 2022 | -0.44 | -0.29 | -51.72% | |
05/12/2022 | -- | Results | Q1 2022 | -0.38 | -0.30 | -25.28% | |
03/29/2022 | -- | Results | Q4 2021 | -0.35 | -0.31 | -12.90% | |
11/04/2021 | -- | Results | Q3 2021 | -0.39 | -0.37 | -6.36% | |
08/05/2021 | -- | Results | Q2 2021 | -0.45 | -0.38 | -18.37% | |
05/06/2021 | -- | Results | Q1 2021 | -0.29 | -0.38 | 23.18% |
*Estimated Date/Time
Earnings
Profile
Edit
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. |
URL | https://www.adverum.com |
Investor Relations URL | https://investors.adverum.com |
HQ State/Province | California |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | Mar. 29, 2023 (est.) |
Last Earnings Release | Nov. 10, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0% |
Forward Yield | -- |
Payout Ratio | -- |
Cash Payout Ratio | -- |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
Revenue (TTM) | -- |
Total Expenses (TTM) | 157.61M |
Net Income (TTM) | -156.21M |
Total Assets (Quarterly) | 332.36M |
Total Liabilities (Quarterly) | 124.02M |
Shareholders Equity (Quarterly) | 208.34M |
Cash from Operations (TTM) | -115.43M |
Cash from Investing (TTM) | 163.37M |
Cash from Financing (TTM) | 0.74M |
Ratings
Profile
Edit
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. |
URL | https://www.adverum.com |
Investor Relations URL | https://investors.adverum.com |
HQ State/Province | California |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | Mar. 29, 2023 (est.) |
Last Earnings Release | Nov. 10, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
ADVM Tweets |